-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Global Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREIQVIA Careers
Featured Careers
Stay Connected
WE'RE HIRING
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESBlog
Peeking into China’s Healthcare Deals
Aug 08, 2018
China’s hospital landscape is rapidly changing as operators and owners respond to shifting policy incentives, an aging population, the opportunity to serve Tier 2 and 3 cities, and shifts in consumer preferences.
One result: growing M&A activity, with assets changing hands in deals involving China’s TTC Franchise Clinics; Beijing Remote Heart Community Hospital; Chengdu New Century Women’s and Children’s Hospital; and Renyi Hospital Company. Some transactions are driven by the desire to consolidate holdings in key cities; others are deals struck to migrate from non-profit to for profit status.
We also are seeing specialty deals in segments such as dental, fertility clinics, eldercare, and nursing homes. Examples include Harmonicare Medical; OUE Lippo Healthcare; Pine Care/Yada JV; and China Cord Blood. These transactions reflect consumer and investor responses to behavioral and demographic shifts: delayed child-bearing has created demand for fertility support; China’s aging population needs more eldercare and nursing homes. We anticipate that such thematic-driven deals will continue.
Beyond these deals, it’s important to note the mindset shift among owners of healthcare assets in China. We are seeing Chinese healthcare operators continue to invest in upgrading their capabilities, their physician mix, and their technology base, e.g. streamlined electronic health records and pharmacy systems. Big thinking is taking place, including ways to capture genetic information and link that to patient records and population health systems – with all the privacy, regulatory and ethical ramifications involved. Combined with growing investment in artificial intelligence and machine learning systems for diagnostic care, important shifts are occurring in China’s care system.
These early stage shifts in China’s treatment landscape in terms of ownership, quality of outcomes, technology systems, and patient preferences is catching investor attention, domestic and foreign. Many of the Chinese owners / operators we talk to want technology and capability partnerships to further differentiate themselves especially in a world in which care starts to become decentralized due to technologies like telemedicine and remote diagnostics.
A number are turning to Singapore, the United States and United Kingdom for potential partners. These partnerships can range from systems design to ongoing capability transfers to equity co-investment. In rare cases, we have also seen Chinese investors consider outright acquisition of US assets to cement those ties rather than simply do a co-branding deal. This Wall Street Journal article “U.S. Hospital Firms, Hungry to Expand, Look to China” provides an excellent overview.
What the future holds is largely dependent on patient flows and policy makers. As US healthcare is increasingly expensive, medical tourism from the US to Asia is likely to rise if US consumers are confident they will receive equivalent treatment outcomes. One Beijing hospital is hoping to provide that level of comfort by having its medical tourism work overseen by an US-based (Ohio) doctor affiliated with the hospital.
We believe there is a largely unexplored option to seize this opportunity. It involves building hospitals and care facilities on both sides of the Pacific, and forming a single global network that allows for profit sharing, patient record sharing, HCP talent exchanges, use of facilities irrespective of location, and cross-referrals, for example. Such a step could help unlock a different end-game for these partnerships rather than one that simply focuses on cash transfers for technology rights. Reinventing the care model in both markets can be the profitable prize especially given forecasts for population growth.
That said, for Chinese hospitals and treatment facilities, the in-country patient pool will always be the dominant source of revenues. China’s aging population, rising purchasing power, and gender mix will force shifts in care, e.g. dental, beauty treatments, home care and fertility treatments. Be that as it may, innovations that draw upon some of the best practices from global markets can also serve the domestic Chinese consumer and patient well.
Those options and others await investors who can partner with Chinese health organizations to reinvent the care model. Feel free to contact me or my consulting colleagues here in Asia to learn more.